JP2022517742A5 - - Google Patents

Info

Publication number
JP2022517742A5
JP2022517742A5 JP2021538378A JP2021538378A JP2022517742A5 JP 2022517742 A5 JP2022517742 A5 JP 2022517742A5 JP 2021538378 A JP2021538378 A JP 2021538378A JP 2021538378 A JP2021538378 A JP 2021538378A JP 2022517742 A5 JP2022517742 A5 JP 2022517742A5
Authority
JP
Japan
Prior art keywords
sequence
strand comprises
antisense
sequence described
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517742A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067883 external-priority patent/WO2020139764A1/en
Publication of JP2022517742A publication Critical patent/JP2022517742A/ja
Publication of JP2022517742A5 publication Critical patent/JP2022517742A5/ja
Priority to JP2024067819A priority Critical patent/JP2024105308A/ja
Pending legal-status Critical Current

Links

JP2021538378A 2018-12-28 2019-12-20 Hmgb1発現を阻害するための組成物及び方法 Pending JP2022517742A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067819A JP2024105308A (ja) 2018-12-28 2024-04-18 Hmgb1発現を阻害するための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862786287P 2018-12-28 2018-12-28
US62/786,287 2018-12-28
US201862787038P 2018-12-31 2018-12-31
US62/787,038 2018-12-31
US201962788111P 2019-01-03 2019-01-03
US62/788,111 2019-01-03
PCT/US2019/067883 WO2020139764A1 (en) 2018-12-28 2019-12-20 Compositions and methods for inhibiting hmgb1 expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067819A Division JP2024105308A (ja) 2018-12-28 2024-04-18 Hmgb1発現を阻害するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2022517742A JP2022517742A (ja) 2022-03-10
JP2022517742A5 true JP2022517742A5 (cg-RX-API-DMAC7.html) 2023-02-24

Family

ID=71128894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538378A Pending JP2022517742A (ja) 2018-12-28 2019-12-20 Hmgb1発現を阻害するための組成物及び方法
JP2024067819A Withdrawn JP2024105308A (ja) 2018-12-28 2024-04-18 Hmgb1発現を阻害するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067819A Withdrawn JP2024105308A (ja) 2018-12-28 2024-04-18 Hmgb1発現を阻害するための組成物及び方法

Country Status (13)

Country Link
US (1) US20220072024A1 (cg-RX-API-DMAC7.html)
EP (1) EP3883581A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022517742A (cg-RX-API-DMAC7.html)
KR (1) KR20210126004A (cg-RX-API-DMAC7.html)
CN (1) CN113874025A (cg-RX-API-DMAC7.html)
AU (1) AU2019417585A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012516A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124664A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021001718A1 (cg-RX-API-DMAC7.html)
IL (2) IL284327B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007855A (cg-RX-API-DMAC7.html)
SG (1) SG11202106857VA (cg-RX-API-DMAC7.html)
WO (1) WO2020139764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675295B2 (en) 2017-06-29 2020-06-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting HMGB1 expression
TW202400790A (zh) * 2022-04-26 2024-01-01 大陸商上海拓界生物醫藥科技有限公司 氘代化學修飾和包含其的寡核苷酸
TWI868755B (zh) * 2022-06-24 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 抑制跨膜絲胺酸蛋白酶6(tmprss6)表現的組成物及方法
CN117264954A (zh) * 2022-09-20 2023-12-22 北京福元医药股份有限公司 用于抑制hmgb1基因表达的双链核糖核酸及其修饰物、缀合物和用途
WO2024233864A2 (en) * 2023-05-10 2024-11-14 Dicerna Pharmaceuticals, Inc. Galnac-conjugated rnai oligonucleotides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
WO2007150071A1 (en) * 2006-06-23 2007-12-27 Myriad Genetics, Inc. Gene amplifications and deletions
WO2011007876A1 (ja) * 2009-07-16 2011-01-20 Necソフト株式会社 Hmgb1結合核酸分子およびその用途
EP2617426B1 (en) * 2010-09-17 2016-08-10 Japan Science and Technology Agency Inhibitor of hmgb protein-mediated immune response activation
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US10351854B2 (en) * 2014-10-10 2019-07-16 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
EP3865576A1 (en) * 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
WO2017079227A1 (en) * 2015-11-05 2017-05-11 University Of Connecticut Compositions and methods for the treatment of liver fibrosis
WO2018045317A1 (en) * 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
US10675295B2 (en) * 2017-06-29 2020-06-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting HMGB1 expression
WO2019126097A1 (en) * 2017-12-18 2019-06-27 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
CN113748208A (zh) 用于抑制中枢神经系统中的基因表达的组合物和方法
TWI924663B (zh) 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
CA3153026A1 (en) Chemical modifications of small interfering rna with minimal fluorine content
AU2022203361A1 (en) Compositions and methods for modulating RNA
CN110832077A (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
TW202130809A (zh) 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
JP2024514880A (ja) Pnpla3発現を調節するための組成物及び方法
WO2023245061A2 (en) Lipid conjugates for the delivery of therapeutic agents to cns tissue
EP4335859A1 (en) Method for designing oligonucleotide having reduced central toxicity
BR112021012516A2 (pt) Composições e métodos para inibir a expressão de hmgb1
WO2025113592A1 (zh) 一种抑制补体系统基因表达的rna抑制剂及其应用
US11634715B2 (en) Methods and compositions for treating bile duct paucity-associated conditions
TW202340471A (zh) 用於抑制冠狀病毒(CoV)病毒基因體之RNAi藥劑、其組合物及使用方法
JP2022520653A5 (cg-RX-API-DMAC7.html)
TW202444904A (zh) 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法
EP1437408A1 (en) Novel antisense oligonucleotide derivatives against hepatitis c virus
EP4704858A1 (en) Sugar modified oligonucleotides and uses thereof
TW202503056A (zh) 用於抑制補體因子B (CFB)之表現之RNAi藥劑、其醫藥組合物及使用方法
EA049851B1 (ru) РНКи-АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ PNPLA3, ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ